Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postherpetic Neuralgia
Conditions
Postherpetic Neuralgia
Trial Timeline
Mar 1, 2015 → Jun 1, 2017
NCT ID
NCT02868801About Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Postherpetic Neuralgia. The current trial status is unknown. This product is registered under clinical trial identifier NCT02868801. Target conditions include Postherpetic Neuralgia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02868801 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Postherpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| QUTENZA | Astellas Pharma | Approved | 85 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| MK-8291 + Placebo | Merck | Phase 1 | 33 |
| Etoricoxib + Placebo | Merck | Approved | 85 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 52 |
| MK0759 | Merck | Phase 2 | 52 |
| MK0686 | Merck | Phase 2 | 52 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 33 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 84 |
| RN624 + RN624 + Placebo | Pfizer | Phase 2 | 51 |
| T-62 | Pfizer | Phase 2 | 51 |
| pregabalin + pregabalin/PF-00489791 + Placebo | Pfizer | Phase 2 | 51 |
| PH-797804 + Placebo | Pfizer | Phase 2 | 51 |
| Placebo + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Approved | 84 |
| T-62 Dose 1 + T-62 Dose 2 | Pfizer | Phase 2 | 51 |
| HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Levetiracetam | UCB | Phase 2 | 49 |